How Many Doses in a Thymalin Vial? (Reconstitution Guide)

Researchers working with Thymalin peptide frequently ask how many doses a single vial contains. But the question itself assumes a fixed answer that doesn't exist. A 10mg vial of Thymalin doesn't contain 'ten doses' or 'twenty doses' inherently. The number of administrations you extract depends on two variables: the volume of bacteriostatic water you use during reconstitution and the dose your protocol requires per administration. A vial reconstituted with 2ml of water yields different dose volumes than the same vial reconstituted with 5ml, even though the total peptide content is identical. This is the single most misunderstood aspect of peptide dosing outside clinical environments.

Our team has guided hundreds of researchers through peptide reconstitution protocols. The gap between doing it right and doing it wrong comes down to three things most online guides never mention: concentration calculation, sterile technique during multi-dose extraction, and storage degradation timelines that render unused peptide inactive long before the vial appears 'empty'.

How many doses are in a vial of Thymalin?

A 10mg Thymalin vial typically yields 10–20 doses depending on your dosing protocol. If reconstituted with 2ml bacteriostatic water and dosed at 1mg per administration, the vial contains 10 doses. If dosed at 0.5mg per administration, the same vial yields 20 doses. The limiting factor is not vial size but concentration. How much peptide sits in each 0.1ml of reconstituted solution.

Direct Answer

Yes, a single 10mg Thymalin vial can yield anywhere from 10 to 20 research doses. But most protocols fail at the reconstitution stage, not the dosing stage. Researchers often assume the peptide quantity in the vial determines dose count without calculating concentration first. The real determinant is peptide-per-milliliter after reconstitution: a 10mg vial mixed with 1ml bacteriostatic water produces 10mg/ml concentration, meaning every 0.1ml drawn contains 1mg of active peptide. If your protocol calls for 0.5mg doses, you draw 0.05ml per administration. Yielding 20 total doses from the same vial. This piece covers exact reconstitution math, sterile multi-dose extraction technique, and the storage timeline that dictates when unused peptide degrades regardless of how much remains in the vial.

Understanding Thymalin Peptide Concentration vs Dose Count

Thymalin is supplied as lyophilised powder in sealed vials. Typically 10mg per vial for research-grade preparations. The peptide itself is stable in powder form when stored at −20°C, but once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days before protein degradation renders it inactive. The number of many doses vial Thymalin yields is determined by solving for concentration: total peptide mass (mg) divided by reconstitution volume (ml) equals concentration (mg/ml). From there, dose volume is calculated by dividing target dose (mg) by concentration (mg/ml).

Example: A 10mg vial reconstituted with 2ml bacteriostatic water produces 5mg/ml concentration. If your protocol requires 1mg per dose, you draw 0.2ml per administration. Yielding 10 total doses. If the protocol requires 0.5mg per dose, you draw 0.1ml per administration. Yielding 20 doses. The vial's peptide content is fixed at 10mg, but dose count scales inversely with dose size. Researchers working with lower-dose protocols extract more administrations from the same vial, provided sterile technique prevents contamination across multiple punctures of the rubber stopper.

The most common mistake: assuming the vial label (10mg) directly translates to dose count without performing concentration math. A 10mg vial does not contain '10 doses' unless your protocol happens to require exactly 1mg per dose and you reconstituted with exactly 1ml of water. Most research protocols call for doses between 0.5mg and 2mg, meaning a single vial can yield anywhere from 5 to 20 administrations depending on titration.

Reconstitution Protocol: How Volume Determines Usable Doses

Reconstitution is the process of dissolving lyophilised Thymalin powder in bacteriostatic water to create an injectable solution. The volume of water you add directly determines peptide concentration and, by extension, how many doses vial Thymalin contains. Standard reconstitution volumes range from 1ml to 5ml depending on dosing precision requirements. Lower volumes yield higher concentrations (making small doses easier to measure), while higher volumes yield lower concentrations (reducing measurement error for researchers without precision syringes).

For a 10mg vial:

• Reconstituted with 1ml water → 10mg/ml concentration → 0.1ml per 1mg dose → 10 total doses at 1mg each
• Reconstituted with 2ml water → 5mg/ml concentration → 0.2ml per 1mg dose → 10 total doses at 1mg each
• Reconstituted with 5ml water → 2mg/ml concentration → 0.5ml per 1mg dose → 10 total doses at 1mg each

Notice the dose count remains 10 across all three scenarios when dosing at 1mg per administration. But the volume you draw changes. Lower reconstitution volumes require drawing smaller, more precise volumes (which demands insulin syringes calibrated to 0.01ml), while higher reconstitution volumes allow larger, easier-to-measure draws. Our experience shows that 2ml is the optimal reconstitution volume for most researchers: it balances concentration (5mg/ml) with measurement ease using standard 1ml insulin syringes marked in 0.01ml increments.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, preventing bacterial growth across the 28-day refrigerated storage period. Sterile water without preservative is unsuitable for multi-dose vials. Any contamination introduced during the first needle puncture will proliferate across subsequent draws. All reconstitution must occur in a sterile field using alcohol-wiped vial stoppers and new syringes for every draw.

Storage Stability and the 28-Day Degradation Window

Once reconstituted, Thymalin remains stable for approximately 28 days when refrigerated at 2–8°C. But this timeline is absolute, not conditional. The peptide begins degrading immediately upon mixing with bacteriostatic water due to hydrolysis, and by day 28, potency loss exceeds 15–20% even under ideal refrigeration. Temperature excursions above 8°C accelerate degradation exponentially: a vial left at room temperature (20–25°C) for 24 hours loses approximately 10% potency, and any exposure above 30°C causes irreversible protein denaturation that neither appearance nor smell can detect.

This creates a practical limit on how many doses vial Thymalin can yield regardless of mathematical concentration. If your protocol calls for 0.5mg doses twice weekly, a 10mg vial yields 20 doses on paper. But administering those 20 doses requires 10 weeks (70 days), which exceeds the 28-day stability window by more than double. In practice, you would discard the vial after 28 days with approximately 60% of the peptide unused. The effective dose count is not 20 but roughly 8 doses before reaching the degradation threshold.

Researchers must calculate not just total doses per vial but doses per stability window. For Thymalin dosed twice weekly at 0.5mg, the 28-day window allows 8 administrations maximum before requiring a fresh vial. For protocols dosed daily at 1mg, a 10mg vial yields 10 doses theoretically but only 10 days of use. Well within the stability window. Frequency and dose size together determine whether you'll use the full vial before degradation renders it inactive. Thymalin from Real Peptides ships in sealed, sterile 10mg vials with batch-specific reconstitution guidance.

Thymalin Dosing Protocols: Dose Count Comparison

What If: Thymalin Dosing Scenarios

What If I Reconstituted My Vial with Too Much Water?

Diluting the peptide below your target concentration doesn't destroy it. It just requires larger draw volumes per dose. If you reconstituted a 10mg vial with 5ml instead of 2ml, your concentration is 2mg/ml instead of 5mg/ml. To achieve a 1mg dose, draw 0.5ml instead of 0.2ml. The peptide content is unchanged; you're simply working with a more dilute solution. The practical constraint is syringe capacity: standard 1ml insulin syringes can't draw 0.5ml accurately in a single pull, so you may need to perform two separate 0.25ml draws or use a larger 3ml syringe. Avoid trying to 'fix' over-dilution by adding more peptide powder to the vial. This introduces contamination risk and makes concentration calculations impossible.

What If I Need Fewer Than 10 Doses from a Vial?

If your protocol requires only 5 doses at 1mg each but you're working with a 10mg vial, reconstitute with 2ml as usual (5mg/ml) and draw 0.2ml per dose. After 5 administrations, you'll have used 1ml (5mg) and 1ml (5mg) remains. The unused portion can be divided into sterile cryovials and frozen at −20°C for future use. Freezing halts degradation indefinitely. Thaw frozen aliquots in the refrigerator (never at room temperature or in a microwave) and use within 28 days of thawing. Each freeze-thaw cycle causes minor protein aggregation, so limit aliquots to one freeze event maximum. This approach prevents waste while maintaining research timeline flexibility.

What If My Vial Has Been Refrigerated for 35 Days?

Discard it. The 28-day stability window is a conservative guideline based on detectable potency loss. By day 35, you're working with a solution that may have lost 20–30% of its peptide activity. Using degraded peptide doesn't produce proportionally reduced results; it produces inconsistent, unreliable results because protein fragments from partial degradation can interfere with receptor binding. There's no home test for peptide potency, and visual inspection is useless (degraded peptide looks identical to fresh peptide). Mark your reconstitution date on the vial with permanent marker and set a calendar reminder for day 28. Our team has reviewed this across hundreds of researchers. Extending beyond the stability window is the single most common source of 'non-responsive' research outcomes.

The Unvarnished Truth About Peptide Vial Yield

Here's the honest answer: most researchers waste 40–60% of every Thymalin vial they purchase. Not because they dose incorrectly, but because they don't match vial size to protocol duration. The industry sells peptides in fixed vial sizes (5mg, 10mg, 20mg) without regard for how those sizes align with realistic dosing schedules, and the result is systematic overbuying. A researcher dosing 0.5mg twice weekly needs 4mg of peptide across a 28-day window. But the smallest available vial is 10mg, meaning 6mg gets discarded at day 28 regardless of sterile technique or storage discipline.

The math is straightforward: if your protocol consumes less peptide per stability window than the vial contains, you're paying for waste. A 10mg vial costs the same whether you use 4mg or 10mg before hitting the degradation threshold. The solution isn't buying smaller vials (they don't exist for most research peptides). It's either adjusting your protocol to higher frequency within the 28-day window or splitting vials into frozen aliquots immediately after reconstitution. Freezing aliquots front-loads the effort but eliminates waste: reconstitute the full 10mg vial with 2ml water, immediately divide into five 0.4ml aliquots (each containing 2mg), freeze four and refrigerate one. Each aliquot supports four 0.5mg doses across 8 days before you thaw the next one.

The alternative. Reconstituting a fresh 10mg vial every 8 weeks for a low-dose protocol. Means buying and discarding five vials to deliver the same peptide quantity you could extract from two vials using aliquot freezing. This isn't about saving money; it's about research integrity. Inconsistent dosing from partially degraded peptide produces inconsistent data, and inconsistent data is worthless data.

Reconstituted Thymalin maintains stable concentration and potency when frozen at −20°C for up to six months. Significantly longer than the 28-day refrigerated window. The freeze-thaw process causes minor protein aggregation (estimated 5–8% potency loss per cycle), but one freeze event is negligible compared to the 20–30% degradation that occurs from extended refrigeration beyond 28 days. Researchers serious about data quality either match their vial size to their protocol duration or adopt aliquot freezing as standard practice. There is no third option that doesn't result in either waste or compromised potency.

Peptide research depends on dosing consistency across timeframes that often exceed single-vial stability windows. The question isn't how many doses vial Thymalin contains in theory. It's how many usable, full-potency doses you can extract before the degradation clock runs out. For most protocols, that number is lower than the vial's peptide content would suggest, and researchers who ignore the stability window are effectively conducting experiments with a variable they can't measure and can't control. If your protocol requires 20 doses from a 10mg vial but spans 10 weeks, you're not conducting a 20-dose study. You're conducting a study where doses 1–8 are full-potency and doses 9–20 are progressively degraded. The results will reflect that inconsistency whether you account for it or not.

Our approach at Real Peptides centres on batch-specific guidance for every vial: reconstitution instructions, concentration tables, and storage timelines based on the exact peptide you're working with. Research-grade peptides like Cerebrolysin and Dihexa follow the same reconstitution principles. The peptide content and stability windows vary, but the math remains identical. If you're unsure whether your protocol aligns with vial size and degradation timelines, contact your peptide supplier before purchasing. A supplier who can't answer concentration questions or provide stability data isn't a supplier worth trusting with research-critical compounds.